C1orf210 Inhibitors
C1orf210 Inhibitors exhibit a diverse range of biochemical actions that lead to the inhibition of the C1orf210 protein function. Rapamycin and PP242, through their inhibition of mTOR, suppress protein synthesis and cell growth pathways that C1orf210 could be involved in, effectively reducing its activity. The PI3K/AKT pathway, essential for cell survival and growth, is targeted by LY 294002 and Wortmannin, both causing a decrease in C1orf210 activity by impairing the pathway's function. SB 203580 and PD 98059, which target the p38 MAPK and MEK pathways respectively, diminish C1orf210's potential involvement in stress response and cellular proliferation processes. The JNK pathway, associated with apoptosis and growth, is modulatedby SP600125, potentially reducing C1orf210 activity through its indirect effects on cell survival mechanisms. Additionally, JWH 073 and U0126 hinder the MAPK/ERK signaling, which could result in decreased functional activity of C1orf210, assuming it is associated with pathways downstream of ERK signaling.
Inhibitors like Roscovitine and Apigenin challenge the cell cycle and growth by targeting cyclin-dependent kinases and CK2, respectively, leading to a potential decrease in C1orf210 activity if it is implicated in cell cycle regulation or survival pathways. BML-275's inhibition of AMPK suggests an indirect reduction of C1orf210 activity by affecting the protein's potential role in metabolic regulation and energy balance. Collectively, these inhibitors accomplish the diminution of C1orf210's function by intricately disentangling and suppressing the complex web of signaling pathways that C1orf210 may be involved in, without directly altering its expression or protein levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, which is a downstream effector in the PI3K/AKT pathway. C1orf210 function is negatively regulated when mTOR activity is suppressed, leading to decreased protein synthesis and cell growth. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it impacts the cellular response to stress and inflammatory cytokines, which could indirectly reduce C1orf210 activity by altering the stress response pathways that it may be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor. By blocking PI3K, it diminishes AKT phosphorylation and subsequent signaling, which would indirectly reduce the activity of C1orf210 by affecting the pathways that control cell survival and growth it may participate in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. It irreversibly inhibits PI3K, leading to the inhibition of the AKT signaling pathway. This could result in diminished activity of C1orf210 by affecting cellular processes such as growth and metabolism it is associated with. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that blocks MAPK/ERK signaling. By inhibiting MEK, it can lead to decreased C1orf210 activity through indirect suppression of the signaling pathways that regulate cellular proliferation and differentiation it may impact. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which modulates apoptotic and growth pathways. Inhibition of JNK would likely result in diminished C1orf210 activity through indirect modulation of cell survival pathways it could influence. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective mTOR inhibitor, which reduces mTORC1 and mTORC2 activity. This leads to a decrease in C1orf210 activity by indirectly inhibiting the mTOR signaling pathway that controls cell growth and proliferation it might be a part of. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a cyclin-dependent kinase inhibitor. It diminishes cell cycle progression which could lead to a decrease in C1orf210 activity if C1orf210 is involved in cell cycle regulation. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin is a flavone that inhibits CK2, which is involved in cell growth and survival pathways. By inhibiting CK2, it could indirectly reduce the activity of C1orf210 if it plays a role in these pathways. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275 inhibits AMPK, which affects energy balance and metabolic stress responses. By inhibiting AMPK, it could indirectly lead to the decreased activity of C1orf210 if it is involved in metabolic regulation. | ||||||